Guardant Health (GH)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Guardant Health (GH)
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Key Insights
Critical company metrics and information
Share Price
$36.87Market Cap
$4.56 BillionTotal Outstanding Shares
123.56 Million SharesTotal Employees
1,779Dividend
No dividendIPO Date
October 4, 2018SIC Description
Services-medical LaboratoriesHomepage
https://www.guardanthealth.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $391.62 Million |
Net Cash Flow From Investing Activities, Continuing | $391.62 Million |
Net Cash Flow | $231.92 Million |
Net Cash Flow From Financing Activities, Continuing | $92.51 Million |
Net Cash Flow From Operating Activities | $-254.07 Million |
Net Cash Flow From Financing Activities | $92.51 Million |
Net Cash Flow From Operating Activities, Continuing | $-254.07 Million |
Net Cash Flow, Continuing | $230.05 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Operating Income/Loss | $-515.14 Million |
Diluted Average Shares | $247.33 Million |
Other Operating Expenses | $863.33 Million |
Net Income/Loss | $-512.41 Million |
Basic Earnings Per Share | $4.28 |
Net Income/Loss Attributable To Parent | $-512.41 Million |
Research and Development | $344.07 Million |
Revenues | $692.26 Million |
Income/Loss From Continuing Operations After Tax | $-512.41 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Diluted Earnings Per Share | $4.28 |
Operating Expenses | $1.21 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Benefits Costs and Expenses | $1.20 Billion |
Basic Average Shares | $247.33 Million |
Costs And Expenses | $1.21 Billion |
Income Tax Expense/Benefit | $27000.00 |
Income/Loss From Continuing Operations Before Tax | $-512.38 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-512.41 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Liabilities | $1.40 Billion |
Noncurrent Assets | $312.01 Million |
Assets | $1.54 Billion |
Liabilities | $1.60 Billion |
Accounts Payable | $15.47 Million |
Liabilities And Equity | $1.54 Billion |
Other Current Assets | $1.15 Billion |
Other Current Liabilities | $181.87 Million |
Current Liabilities | $197.34 Million |
Equity | $-60.10 Million |
Other Non-current Assets | $179.59 Million |
Inventory | $72.30 Million |
Fixed Assets | $125.17 Million |
Intangible Assets | $7.25 Million |
Equity Attributable To Parent | $-60.10 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Assets | $1.23 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.